Brief: Genocea Announces Positive Interim Immunogenicity Data From Gen-009 Neoantigen Vaccine Phase 1/2A Clinical Trial
16/05/2019 13:18
May 16 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA ANNOUNCES POSITIVE INTERIM IMMUNOGENICITY DATA
FROM
GEN-009 NEOANTIGEN VACCINE PHASE 1/2A CLINICAL TRIAL
* GENOCEA BIOSCIENCES INC - POST-VACCINATION IMMUNE
RESPONSES
DETECTED TO 93% OF VACCINE NEOANTIGENS IN FIRST THREE PATIENTS
ANALYZED
Source text for Eikon: ID:nGNX2mgYmc
Further company coverage: GNCA.O
((Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc